Rice University researchers in the lab of chemist Han Xiao have identified a promising new immunological pathway to treat stubborn bone tumors, one of most prevalent forms of metastases in breast cancer patients.
ABBV-101 by AbbVie for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes